cyrilzakka/clinical-trials huggingface dataset:
Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section

Postpartum hemorrhage (PPH) is the primary cause of nearly one quarter of all maternal deaths globally. Management of uterine tone after delivery involves giving a prophylactic uterotonic and the use of controlled cord traction to facilitate delivery of the placenta and minimize blood loss. Syntocinon and carbetocin are the most commonly used drugs ,During caesarean delivery of stenotic valvular disease patient, the anesthesiologist have an important question: what is the best drug used for prevention of PPH with minimal hemodynamic effect regarding Systemic vascular resistance (SVR), Cardiac out put (COP),Heart rate ( HR), blood pressure? As uterotonic drugs may cause severe hypotension, decrease in SVR and COP that may not be tolerated by these patients .this thesis aims to compare between syntocinon and carbetocin regarding their effect on cardiac output and systemic vascular resistance using cardiometry in cardiac patients with stenotic lesions during caesarean delivery.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant female single tone \>38 weeks
* Age :18-45 years old.
* patient with ASA III
* Cardiac patients ( mild and moderate mitral stenosis-aortic stenosis valve disease )

Exclusion Criteria:

* Other cardiac conditions (valve regurge, cardiomyopathy, heart failure,severe mitral stenosis, severe aortic stenosis, severe pulmonary hypertension)
* Pregnancy hypertensive disorders (eclampsia,preeclampsia)
* Abnormal placental attachment (accrete,percreta,increta)
* Patients with bleeding disorders
* patient with high risk of postpartum haemorrhage
Awareness of Gestational Diabetes Among Sohag Governorate Women

The type of the study is a cross sectional descriptive using questionnaire method in Sohag governorate among 500 Women, over 6 months by random selection and they will be asked to answer the questions of prepared and copied questionnaire sheet.

Inclusion criteria: all women can participate in this questionnaire.

the study is a cross sectional descriptive using questionnaire method in Sohag governorate among 500 women, over 6 months by random selection and they will be asked to answer the questions of prepared and copied questionnaire sheet. Data was collected by using a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to Gestational Diabetes Mellitus (GDM) were included. Final version of questionnaire consists of 15questions divided into five main categories which are basic knowledge about GDM(3 questions), risk factors (3 questions), food and diet values (3 questions), management(3 questions)and complications/outcomes (3 questions). All questions were in multiple choice format with one option was "I don't know "to avoid unnecessary guesses by the participants. Score 1 was given to every right answer and 0 to every wrong answer. A higher score indicates better knowledge about GDM. Thus the maximum score is 15 and minimum is 0 and other questions without score to know the patient himself and to assess the relationship between the residency, work, education level and knowledge of patient and family history.

A standardized questionnaire will focus on:

1. Personal Data
2. Basic Knowledge about GDM
3. Knowledge about risk factors of GDM
4. Knowledge about diet/food values
5. Knowledge about management of GDM
6. Knowledge about GDM complications/outcomes

Eligibility Criteria:
Inclusion Criteria:

* All Females

Exclusion Criteria:

* There is no Exclusion Criteria:
The Relationship Between Diaphragm Muscle Thickness and Fibromyalgia

Fibromyalgia syndrome is characterized by chronic pain, fatigue, sleep problems and functional symptoms. Fatigue, anxiety and depression disorders, poor quality of life, sleep disorders, decreased concentration, and impaired cognitive functions are non-specific pain-related symptoms.

Various studies have reported decreased chest expansion, maximal ventilatory volume and maximal expiratory pressure in fibromyalgia patients with widespread body pain. Additionally, dyspnea is a symptom associated with respiratory muscle weakness and is associated with general fatigue. In these individuals, lower data are obtained in daily living activities and general health evaluation surveys. We did not find any study in the literature regarding the relationship between diaphragm thickness and fibromyalgia symptoms. In the light of these data, we aimed to evaluate the thickness of the diaphragm, one of the most important inspiratory muscles, in fibromyalgia patients.

Demographic information of all individuals included in the study will be collected. Daily living activity will be evaluated with Short Form-36 (SF-36), Fibromyalgia Impact Questionnaire (FIQ), Pittsburgh Sleep Quality Questionnaire (PSQI) and Beck Depression Inventory. In order to evaluate the respiratory function test in both the fibromyalgia and control groups, three consecutive measurements will be taken with a hand spirometer and the arithmetic average of these three measurements will be recorded. In fibromyalgia and control patients, diaphragm thickness was measured at 8-9 degrees on the right anterior axillary line with a 6-14 Mhz linear, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD., P.R. China) in the supine position. It will be measured at the end of inspiration and expiration from the intercostal space. Three measurements will be made and the arithmetic average will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with fibromyalgia according to the 2016 ACR (American College of Rheumatology) diagnostic criteria without any comorbidities (such as liver, kidney failure, DM, rheumatic disease)
* Patients who underwent Pulmonary Function Test (PFT)
* Patients without pulmonary disease
* 18 -50 years old women and men

Exclusion Criteria:

* Congenital spinal, costal and diaphragmatic anomalies neuromuscular disease
* Respiratory system diseases that affect lung functions
* Patients who cannot cooperate with spirometry.
* Having surgery to the chest wall or spine
* Those with BMI \> 25
* Those with liver, kidney failure, DM, rheumatic disease, neurological disease
* Individuals \< 18 years and \> 50 years old
White Matter Hyperintensities Burden in Adult Patients With Cyanotic Congenital Heart Disease: a Pilot Study

The study aims at investigating the role of cyanotic congenital heart disease (cCHD) on brain aging. The investigators assume that due to congenital and acquired cardiovascular abnormalities, cCHD patients could show radiologic (and clinical) signs of precocious brain aging and eventual cognitive decline.

White matter hyperintensities burden will be quantified through a semi-autamated software (ITK-SNAP)

Eligibility Criteria:
Inclusion Criteria:

* for the patient group, being an adult subject affected with cyanotic congenital heart disease, whether surgically corrected or not.
* for the control group, being an healthy subject.

Exclusion Criteria:

* any contraindication to magnetic resonance imaging;
* any pathological condition and/or symptomp that could alter the white matter hyperintensities burden, among which:

  * inflammatory, infectious, demyelinating or dysmyelinating diseases of the CNS;
  * ischemic, haemorrhagic or traumatic brain events and eventual gliotic and malacic or lacunar sequelae;
  * genetic diseases (whether mendelian or mitochondrial) of the CNS;
  * cerebral amyloid angiopathy;
  * CADASIL;
  * cerebral arteriovenous malformations;
  * primary or metastatic brain neoplasms which cause neurological symptoms and/or brain parenchymal sequelae from surgical excision;
  * patent oval foramen;
  * being pregnant;
  * migraine with aura (Bashir, Lipton, Ashina, \& Ashina, 2013).
Metabolism of Branched-chain Amino Acids in Monocyte/Macrophage During Sepsis

The current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

In this study, the investigators will collect the peripheral blood of 1,3,7,14 day after diagnose of sepsis. Then, the concentration of branched-chain amino acids(BCAAs) in monocytes and plasma, and the expression of BCAAs metabolic enzymes in monocytes will be determined. Additionally, the inflammatory cytokines, e.g., Interleukin-1β (IL-1β), Tumor necrosis factor-α (TNF-α), Interleukin-10 (IL-10）, the chemokines macrophage inflammatory proteins 1α and 1β (MIP-1α and 1β) in the peripheral blood and the phagocytic function of monocytes will also be detected. The current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

Eligibility Criteria:
Inclusion Criteria:

* patients diagnosed with sepsis, with or without type 2 diabetes
* healthy volunteers

Exclusion Criteria:

* patients with immunodeficient diseases
* patients who accept glucocorticoid or immunosuppressant
* patients with an age younger than 18 years
* patients who cannot provide the informed consent
Management of Large Retained Products of Conception (> 4 cm): Need for an Standardized Procedure.

Collection of relevant data form patients who were treated in the Ghent University Hospital in the context of a placental remnant lager than 4 cm, performing statistical analyzes on the collected data, reviewing the literature on the subject and formulation of a recommendation for treatment of these large placental remnants.


Eligibility Criteria:
Inclusion Criteria:

* retained products of conception larger than 4 cm in largest dimension

Exclusion Criteria:

* retained products of conception 4 cm or smaller in largest dimension
Acupuncture Research on Lung Cancer Patients With Cancer Related Fatigue（CRF）

we plan to conduct this trial to find out：

* If acpuncture treatment could relieve CRF among lung cancer patients receiving chemo- or radio-therapy？
* How about the extent it relieves？the safety and applicability ？
* What's the possible influential factor and mechanism ？


Eligibility Criteria:
Inclusion Criteria:

* Patients who are pathologically/cytologically diagnosed as NSCLC and received radiotherapy with or without chemotherapy, and the last radio- or chemo-therapy must be at least 30 days prior to initiation of experimental treatment;
* Participants who meet the diagnosis criteria of CRF（ICD-10 criteria);
* The first time to receive acupuncture treatment;
* The age is between 18 and 65 years old;
* Mean baseline fatigue as measured by the Brief Fatigue Inventory (BFI) must be four or above;
* ECOG performance status 0, 1 or 2.
* Patients must have adequate organ functions reflected by the laboratory criteria below: neutrophil counts ≥ 1.5×109 /L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 85 g/L, Serum creatinine \< 2.0 mg/dL, Bilirubin \< 1.5 mg/dL, ALT \< 3 x normal, albumin \>30g/L.
* Have not taken any hypnotic, melatonin, or antidepressants within 30 days;
* Willing to finish the whole observation period;
* With written consent form signed by themselves.

Exclusion Criteria:

* Participants in other clinical research;
* Can not be pathologically or cytologically diagnosed as NSCLC;
* ECOG 3\~4;
* Pregnant woman;
* \>65 or \<18 years old;
* Patients with evidence of any cognitive dysfunction that would limit their abilities to report fatigue;
* Patients who have received acupuncture ever before;
* Received surgery, immunotherapy or target therapy within one month before the recruition；
* Taking warfarin or heparin, a bleeding tendency exists;
* Infection, ulceration or hyperalgesia at or near the local acupoints' skin，or with active infections；
* There are cerebral vascular accident history or spinal cord injury history；
* Combination with other serious diseases or condition, including congestive heart failure, Unstable angina pectoris, myocardial infarction during the past six months, serious's arrhythmia, mental disorders, drug abuse, etc.;
* Patients with a life expectancy \< 3 months;
* Patients with a past history of therapy or scheduled visits non-compliance, as determined by their treating physician.
The Metaphyseal Hip Prosthesis - Total Hip

The purpose of this study is to analyze stability, safety and efficacy of the Metaphyseal Hip Prosthesis (MHP) compared to the Stanmore hip replacement.

The purpose of this study is to analyze stability, safety and efficacy of the Metaphyseal Hip Prosthesis (MHP) compared to the Stanmore hip replacement at short term (1 year) and long term (10 years).

Bone remodeling will be analyzed at 10 years using DEXA (Dual Energy X-Ray Absorptiometry (bone scan test)) measurements.

This is a single-center prospective study with 25 patients in the study and 25 in the control group in open Randomized Clinical Trial.

Eligibility Criteria:
Inclusion Criteria:

* Candidates for a total hip replacement because of arthritis of the hip
* Patients with a good general condition
* Patients willing and able to participate in the clinical trial with a 10 years follow up and who have signed an inform consent
* Males and females
* Age between 55 and 75
* Absence or little presence of osteoporotic bone (t\>-2)
* ASA score 1 and 2

Exclusion Criteria:

* Patient with co morbidities that limit the physical abilities which may negatively influence the scores. Such co morbidities can for example be cardiac insufficiency or chronic respiratory diseases.
* Severe systematic diseases such as rheumatic arthritis and SLE.
* General osteoporosis (t\<-2).
* Hormonal conditions such as Paget disease, which reduces the bone density.
* Diseases that can negatively influence the 10 years life expectancy.
* Chronic use of corticosteroids.
* Extreme overweight defined as BMI above 35.
* Active bacterial infection.
* Mental weakness which could negatively influence the postoperative recovery and influence the ability to complete pain scores and other questionnaires.
* ASA score \>2.
Mechanism of EGR2 in Allergic Rhinitis

EGR2 may be a target for the treatment of nasal polyps.

There is much debate about the etiology of nasal polyps, so the pathogenesis of nasal polyps still needs to be clarified. Surgery for noninflammatory nasal polyps may be better control, but surgery is not effective for recurrent sinusitis and nasal polyps. Therefore, more research is needed to determine the best targeted therapy for nasal polyps. We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitis.In addition, the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group, and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis. EGR2 may be involved in the pathogenesis of nasal polyps, and may also be related to the severity and recurrence of nasal polyps. EGR2 may be a target for the treatment of nasal polyps.

Eligibility Criteria:
Inclusion Criteria:

All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study.

Exclusion Criteria:

Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.
Longitudinal Study of Patients Following Long Bone Fracture

Studies in chickens show that blood levels of a particular form of vitamin D (called 24,25-dihydroxvitamin D) increase after bone fracture. Laboratory studies show that this form of vitamin D helps the bone healing process in chickens. The investigators want to find out whether blood levels of this form of vitamin D increase after bone fracture in humans. Previous research studies have not addressed this question. The results of this research could eventually lead to the development of new treatments to help bone healing after fracture.

Patients will be asked to take part in this study if they are aged 16 years or older and come to the Royal London Hospital with a broken bone in the arm or leg or collar bone (clavicle). They will be asked to give a 20ml (about 4 teaspoons) blood sample on three occasions: at the start of the study, at 5-14 days after the fracture; and at 4-10 weeks after the fracture. The rest of their normal care would not be affected. Follow-up blood samples will be timed to coincide with routine clinic visits which are scheduled as part of normal clinical care. Patients' vitamin D level will be measured as part of the study, and those who have a low vitamin D level will be informed about this, and advised about appropriate vitamin D supplementation. The investigators will let the patient or their GP know if any blood tests are abnormal


Eligibility Criteria:
Inclusion Criteria:

1. Any cross-shaft long bone or clavicle fracture within last 12 hours
2. Able to give written informed consent
3. Age ≥ 16 years
4. Fused physes (physiologically adult)

Exclusion Criteria:

1. Taking medication affecting vitamin D metabolism - carbamazepine, phenobarbital, phenytoin or primidone
2. Taking vitamin D supplement \> 800 IU/day
3. Abdominal visceral injury, pleural injury (except pneumothorax), spinal cord injury, or GCS \< 15 at presentation to hospital
4. Known Paget's disease, osteopetrosis, metastatic bone cancer, or primary bone cancer
5. Current prisoners
6. Currently taking part in another clinical research project
Decline in Renal Concentration Ability in Lithium Treated Patients

Lithium therapy is cornerstone in therapy of bipolar disorders. A well known side-effect of lithium therapy is a urinary concentration defect which manifests in it's most severe form as nephrogenic diabetes insipidus. The development of urinary concentration defects and its progression to nephrogenic diabetes insipidus in the population of lithium treated patients is unknown and therefore this study aims to evaluate the decline of urinary concentration defects in a Dutch population of lithium treated patients. In this prospective cohort study, 51 participants treated with lithium at Canisius Wilhelmina Hospital, Nijmegen and included in the previous study in 2012 will be approached to undergo a follow-up dDAVP-test.


Eligibility Criteria:
Inclusion Criteria:

* included in the previous study
* men and women
* age ≥ 18 years

Exclusion Criteria:

* General contra-indications for participation in a trial:

  * inability to give informed consent
  * pregnancy
  * unstable psychiatric condition
* Alternative causes of (nephrogenic) diabetes insipidus:

  * hypokalemia (plasma potassium \< 3.0 mmol/l)
  * severe hypercalcemia (albumin-corrected plasma calcium \> 2.80 mmol/l)
  * hyperglycemia (plasma glucose \> 10.0 mmol/l)
  * history of amyloidosis, Sjögren's syndrome or Sickle cell anemia
  * previous treatment with ifosfamide
  * established primary polydipsia or central diabetes insipidus
* Contra-indications for dDAVP administration:

  * inability to comply with water restriction
  * renal insufficiency (GFR \< 45 ml/min/1.73 m2)
  * hyponatremia (plasma sodium \< 130 mmol/l)
  * instable angina pectoris
  * decompensated cardial insufficiency
* Other:

  * concomitant treatment with desmopressin or democlocycline
Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

To evaluate the safety and feasibility of adipose-derived regenerative cells injected into tears of the hamstring muscle.

The RECOVER Clinical Trial is a prospective, randomized, multi-center device trial intended to assess safety and feasibility, and inform dose selection in preparation for a pivotal trial. Subjects that have Grade II tears of the hamstring will be evaluated for eligibility in this study.

Part A of the trial will be an open-label, safety, feasibility and dose-escalation study to assess whether the treatment approach (liposuction, cell processing and injection) is feasible in athletic patients at one or both doses of ADRCs.

Part B of the trial is contingent on successful completion of Part A and is a multicenter, randomized, double blind trial of both doses of ADRCs vs. placebo.

In both parts of the study, following informed consent and screening evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo liposuction under general or local anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs for immediate intramuscular administration under ultrasound guidance.

The first 5 patients of Part A will receive 0.2 million cells/kg body weight (maximum of 20 million cells) while the second 5 patients will receive 0.4 million cells/kg body weight (maximum of 40 million cells).

If the study is shown to be safe and feasible in Part A then patients in Part B of the study will be randomly assigned to receive one of two doses of ADRCs or a visually-matched placebo in a 1:1:1 ratio. If they receive the placebo they will undergo a liposuction and sham intramuscular injection procedure in which they will receive placebo.Part B will receive placebo, 0.2 million cells/kg body weight (maximum of 20 million cells), or 0.4 million cells/kg body weight (maximum of 40 million cells).

Patients in Part A of the study will be followed through to 90 days post-procedure. Patients in Part B of the study will be followed through to 24 months post-procedure.

Eligibility Criteria:
Inclusion Criteria:

* Grade II tears (≥5%) of the hamstring
* Weakness or inability to use affected muscle
* Ability to safely undergo liposuction

Exclusion Criteria:

* Tears restricted to the ligament (i.e. no muscle tear)
* Known spine or disc disease or sciatic nerve disease
* Known neuromuscular disease
* Pregnant or lactating status
* Any condition requiring immunosuppressive medication or use of systemic steroids
* Known history of HIV, or has active Hepatitis B or active Hepatitis C
* Cancer requiring chemotherapy or resection within the last 5 years (other than basal cell carcinoma)
Frequency of Putative Enteric Zoster Diagnosed Using Saliva Samples in Patients With Abdominal Pain: a Prospective Study

The aim of this study is to identify the frequency of enteric zoster using salivary varicella zoster virus (VZV) DNA PCR in patients who visit the emergency room due to acute abdominal pain.

Varicella zoster virus (VZV) infects and establishes latency in neurons in the ganglia of the cranial nerve, dorsal root, and enteric ganglia. VZV reactivation in enteric neurons (enteric zoster) can cause nonspecific abdominal pain and/or serious gastrointestinal dysfunction without cutaneous manifestations. Detection of VZV DNA in saliva may be useful for identifying enteric zoster. We evaluated the frequency of putative enteric zoster based on the presence of salivary VZV DNA in patients with acute abdominal pain.

Adult patients who visited the emergency room due to moderate to severe acute abdominal pain were prospectively enrolled at a tertiary hospital between May 2019 and November 2019. Abdominopelvic computed tomography (APCT) was performed in all patients. Saliva samples were collected from all studied patients. Enteric zoster was suspected based on the presence of salivary VZV DNA, detected using real-time polymerase chain reaction (PCR).

Eligibility Criteria:
Inclusion Criteria:

* Patients aged ≥ 18, and \< 80 years
* ER-visited patients with acute abdominal pain

  * Numerical rating scale (NRS) score ≥ 4
  * Unresponsive to gastrointestinal motility drug, antacid

Exclusion Criteria:

* Unwilling or unable to give informed consent forms
* Patients taking antiviral agents
* Patients complaining mild abdominal pain (NRS score ≤ 3)